J. Hii

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab

M. Derde, T. Petit, X. Pivot, 2021, PloS one.

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting

G. Bonamy, M. Derde, X. Pivot, 2022, JAMA oncology.